{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01443689",
      "OrgStudyIdInfo": {
        "OrgStudyId": "BKCR-BURN-1.0(2011)"
      },
      "Organization": {
        "OrgFullName": "Shenzhen Beike Bio-Technology Co., Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Allogenic Stem Cell Therapy in Patients With Acute Burn",
      "OfficialTitle": "A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Acute Burn"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2012",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 2011"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 2013",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "July 2013",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "September 27, 2011",
      "StudyFirstSubmitQCDate": "September 29, 2011",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 30, 2011",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "November 26, 2012",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 28, 2012",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Shenzhen Beike Bio-Technology Co., Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "The Second Affiliated Hospital of Kunming Medical University",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Burn trauma,especially extensive ones, remains a life-threatening local and general inflammatory condition destroying the skin and underlying tissues, and resulting in serious sequelae. Remarkable progress has been achieved during last 30 years，stem cell therapy plays an important role in this progress. Human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells (hCBMNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy for burn. In this study, the safety and efficacy of hUCMSCs and hCBMNCs transplantation will be evaluated in patients with acute burn.",
      "DetailedDescription": "To investigate the safety and efficacy of human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells transplantation in patients of Acute, Moderate-Severe, Full-thickness burn."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Burns"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Extensive Burn",
          "Human Cord Blood Mononuclear Cells",
          "Human Umbilical Cord Mesenchymal Stem Cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Group1 :Conventional plus hUCMSCs treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: human umbilical cord mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Group 2: Conventional plus hCBMNCs and hUCMSCs therapy",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Group 3:Conventional therapy",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Participants will be given conventional therapy only with a 6 months follow-up.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Conventional therapy"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "human umbilical cord mesenchymal stem cells",
            "InterventionDescription": "Participants will be given conventional therapy plus hUCMSCs transplantation.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group1 :Conventional plus hUCMSCs treatment"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells",
            "InterventionDescription": "Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group 2: Conventional plus hCBMNCs and hUCMSCs therapy"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Conventional therapy",
            "InterventionDescription": "Participants will be given conventional therapy only.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group 3:Conventional therapy"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "The ratio of wound contraction and re-epithelialisation",
            "PrimaryOutcomeTimeFrame": "6 months after treatment"
          },
          {
            "PrimaryOutcomeMeasure": "Complete healing time for investigated burn area",
            "PrimaryOutcomeTimeFrame": "6 months after treatment"
          },
          {
            "PrimaryOutcomeMeasure": "Vancouver Scar Scale",
            "PrimaryOutcomeTimeFrame": "6 months after treatment"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Incidence of infections and bleedings in burn wounds",
            "SecondaryOutcomeTimeFrame": "6 months after treatment]"
          },
          {
            "SecondaryOutcomeMeasure": "Engraftment assessment: Vitality of the graft",
            "SecondaryOutcomeTimeFrame": "6 months after treatment]"
          },
          {
            "SecondaryOutcomeMeasure": "McGill pain Questionnaire",
            "SecondaryOutcomeTimeFrame": "6 months after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence of Adverse Events and Serious Adverse Events",
            "SecondaryOutcomeTimeFrame": "6 months after treatment"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nBetween age 18- 65 years, both gender.\nDiagnosed with Acute, Moderate-Severe, full-thickness burn:\n\nBurn occurring within the 72 hours prior to administration. TBSA 20-55%, third degree wounds surface area < 19 % ;\n\nWilling to sign the Informed Consent Form.\n\nExclusion Criteria:\n\nAll other burns except thermal origin.\nChronically malnourished, poor medical condition or shock\nSystemic inflammatory response syndrome (SIRS) or septicopyemia\nModerate-severe inhalation injury airways to lung\nHIV+\nAutoimmune disease, e.g. lupus erythematosus, multiple sclerosis.\nSevere pulmonary and hematological disease, malignancy or hypo-immunity.\nCurrently undertaking other treatment that may affect the safety/efficacy of stem cells.\nPregnancy or lactation\nEnrollment in other trials in the last 3 months.\nOther criteria the investigator consider improper for inclusion.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Jinfeng Fu",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-871-5351281",
            "CentralContactEMail": "ynfjf@hotmail.com"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "The Second Affiliated Hospital of Kunmming Medical College",
            "LocationStatus": "Recruiting",
            "LocationCity": "Kunming",
            "LocationState": "Yunnan",
            "LocationZip": "650033",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Jinfeng Fu",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "86-871-5351281",
                  "LocationContactEMail": "ynfjf@hotmail.com"
                },
                {
                  "LocationContactName": "Jinfeng Fu",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000002056",
            "ConditionMeshTerm": "Burns"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000014947",
            "ConditionAncestorTerm": "Wounds and Injuries"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M4478",
            "ConditionBrowseLeafName": "Burns",
            "ConditionBrowseLeafAsFound": "Burn",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M16837",
            "ConditionBrowseLeafName": "Wounds and Injuries",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC26",
            "ConditionBrowseBranchName": "Wounds and Injuries"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}